Stem Cells: Myths and Misconceptions in the Public Eye
Stem Cell therapy constitutes one of the most hailed advents in medicine for its potential […]
Stem Cell therapy constitutes one of the most hailed advents in medicine for its potential […]
Clinical trials are complex undertakings, with complex planning required. Success or failure is often determined long before the trial even gets underway. Biorasi’s quintessential guide to clinical trial planning helps program managers and operations directors identify and resolve the sticking points that can risk the timely completion of their clinical trials and programs.
With a global market of USD 3.3 billion during 2016 and a forecast surpassing USD […]
Immunoglobulin A (IgA) is an antibody manufactured by the body’s immune system to protect against invaders. […]
Despite an extremely encouraging 38% decrease in mortality since 1989, Breast Cancer remains the most common […]
It is estimated that the number of PD cases is likely to grow significantly as populations grow older around the world and it is predicted that PD prevalence will at least double by 2030 in the US alone. As a result, it has become increasingly clear that these novel PD treatments and others need to be advancing to reach the clinical realm.
According to the CDC, post-traumatic stress disorder (PTSD) is one of the most common mental disorders […]
Clinical research in dermatology has a reputation for being simple and easy to conduct compared to […]
For this week’s Biorasi Spotlight, meet Jennifer Royzis, Lead, Talent Acquisition at Biorasi, LLC.
How did you get […]
A Modern Approach to Patient Education Increases Enrollment
Not every study presents a completely new and unique set of challenges. That’s not to say that the trial is generic, or not complex, but rather that Biorasi’s past work covers a large breadth and depth of experience. That experience allows us to see a lot of potential trial-stopping issues before they happen, and account for them in our planning. When we were asked to complete a trial on an acute lower back pain medication, we needed to identify potential pitfalls early in the planning process to make sure they wouldn’t lead to surprises later.
Flexibility and Strong Process-driven Planning Overcomes Regulatory Speed-bumps